Not FDA-approved1,3Evidence: Smaller human trialsLiver

Efinopegdutide1

Also called HM12525A, JNJ-645651111

Key takeaway

Efinopegdutide is an experimental agonist of both the GLP-1 and glucagon receptors, built from an oxyntomodulin analogue linked by polyethylene glycol to part of a human antibody, studied for fatty liver disease.1,2 In a 24-week phase 2a trial of 145 people with non-alcoholic fatty liver disease, it cut liver fat by 72.7% on average, compared with 42.3% for semaglutide.2 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,3,5

Efinopegdutide at a glance

What it isAn oxyntomodulin analogue conjugated by a polyethylene glycol linker to a human IgG4 Fc fragment, also coded HM12525A and JNJ-64565111, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3
Human evidenceA 24-week phase 2a randomized, open-label trial in 145 people with non-alcoholic fatty liver disease, compared with semaglutide.2
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is efinopegdutide?

Efinopegdutide is a modified analogue of the hormone oxyntomodulin joined by a polyethylene glycol linker to the Fc portion of a human IgG4 antibody, according to FDA’s substance registry.1

The registry also records the codes HM12525A and JNJ-64565111.1

How is efinopegdutide thought to work?

FDA’s substance registry records it as an agonist of the GLP-1 receptor and the glucagon receptor.1

The trial authors write that GLP-1-driven weight loss can reduce liver inflammation, and that acting on the glucagon receptor may also reduce liver fat directly by increasing fat burning and reducing fat production in the liver.2

What do human studies show?

In a 24-week open-label trial, 145 people with at least 10% liver fat were randomly assigned to efinopegdutide or semaglutide. Liver fat fell by 72.7% on average with efinopegdutide and 42.3% with semaglutide, a significant difference.2

Weight fell by 8.5% and 7.1% respectively, a difference that was not significant. Side effects, mainly gastrointestinal, were slightly more common with efinopegdutide.2

What the evidence base contains

  • Controlled human trial A phase 2a randomized, active-comparator-controlled, open-label trial in 145 people with non-alcoholic fatty liver disease, in which liver fat fell by 72.7% with efinopegdutide and 42.3% with semaglutide after 24 weeks.2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is efinopegdutide FDA-approved?

None of the sources reviewed here reports an approval of efinopegdutide by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efinopegdutide.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efinopegdutide is not among them.4,5

Timeline

  1. A phase 2a trial comparing efinopegdutide with semaglutide in fatty liver disease is published.2

What is still unknown?

Whether reducing liver fat translates into less liver inflammation and scarring, which the 24-week trial measured only by imaging.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Efinopegdutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Efinopegdutide are a bounded selection, not every registration or paper about Efinopegdutide. For the years before Efinopegdutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Efinopegdutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Efinopegdutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied in clinical trials. Published evidence is a 145-person phase 2a trial. Efinopegdutide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Efinopegdutide?

No FDA approval reported; studied in clinical trials. Published evidence is a 145-person phase 2a trial. Efinopegdutide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
4
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Efinopegdutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

10Selected dated records
15Connected citations
4Populated source years2019–2026
2/4Record lanes present

Registered human studies

Trial composition

9 of 9 selected trial records include at least one phase value; 9 of 9 include a status value in the retained structured contract.

PhasesPhase 1 7Phase 2 2
Status at observationCompleted 9

PubMed bibliography

Publication composition

1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
10

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 10 dated records

Research hub

Explore the Efinopegdutide evidence record

Open all 10 records →
10Dated records
2Evidence types
10Cited public sources
4Source years

Change ledger

Recently changed for Efinopegdutide

Open all 10 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03235219

PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.

PeptideScanner change date
November 16, 2026
Cited source date
April 27, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03546205

PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.

PeptideScanner change date
November 16, 2026
Cited source date
April 27, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03586843

PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide.

PeptideScanner change date
November 16, 2026
Cited source date
April 16, 2019
Evidence lane
Clinical trials

Official-source collections

Source records for Efinopegdutide

Open the full research atlas →
ClinicalTrials.gov9

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06465186Registry update September 21, 2026 · completed at observation
  2. NCT06482112Registry update June 1, 2026 · completed at observation
  3. NCT06052566Registry update October 22, 2025 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span April 16, 2019 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 10

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Efinopegdutide: a step towards precision in MASH therapy?↗

    PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT06465186↗

    PeptideScanner retained ClinicalTrials.gov record NCT06465186 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT06482112↗

    PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06052566↗

    PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03235219↗

    PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT03546205↗

    PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT06701305↗

    PeptideScanner retained ClinicalTrials.gov record NCT06701305 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT06836037↗

    PeptideScanner retained ClinicalTrials.gov record NCT06836037 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT03606057↗

    PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT03586843↗

    PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Efinopegdutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease (2023) · PMID 37355043 ↗

    Journal of Hepatology · Official source · Source checked November 16, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026